A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease - Trial NCT05804383
Access comprehensive clinical trial information for NCT05804383 through Pure Global AI's free database. This Phase 1 trial is sponsored by Allyx Therapeutics and is currently Recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Allyx Therapeutics
Timeline & Enrollment
Phase 1
Mar 28, 2023
Jul 15, 2024
Primary Outcome
Stage 1 and Stage 2 Incidence of treatment-emergent adverse events (TEAEs),Stage 1 and Stage 2 Incidence of clinically significant lab abnormalities,Stage 1 Incidence of clinically significant changes in safety assessments,Stage 2 Incidence of clinically significant changes in safety assessments
Summary
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in
 Healthy Older Adults and Patients with Alzheimer's Disease
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05804383
Non-Device Trial